Marvel Biosciences Corp. (MBCOF)

Market Cap	2.95M
Revenue (ttm)	n/a
Net Income (ttm)	-1.15M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7,802
Open	0.0789
Previous Close	0.0789
Day's Range	0.0789 - 0.0789
52-Week Range	0.0365 - 0.1244
Beta	0.68
RSI	69.28
Earnings Date	Jun 18, 2025

About Marvel Biosciences

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Ca...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: J. Matheson
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: MBCOF

Financial Performance

Financial numbers in CAD